Search PubMed⌕ Search

Biomedical subjects

E Yanagawa

Publications and source records attributed to E Yanagawa.

5 recordsLinked to original sources
PubMed1979

Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin.

Nonspecific adjuvant immunotherapy with Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) was given to 155 lung cancer patients. Clinical effects of the BCG-CWS treatment were estimated by comparing the survival of the BCG-CWS group with that of a historical control group on the basis of 4-year results. Significant prolongation of survival time has been observed in Clinical Stages II, III (M0) and III (M1). However, most Stage III patients who were given the BCG-CWS treatment died of cancer itself after marked prolongation of survival time. An increase in complete cure rate has been expected only in Stages I and II. Surgicopathological staging was used in resected cases. Resected cases at any stage were sensitive to treatment with BCG-CWS. Histologically, all types of lung cancer including squamous cell carcinoma, adenocarcinoma, and anaplastic carcinoma were sensitive to treatment with BCG-CWS. Intrapleural administration of BCG-CWS to patients with malignant pleurisy was effective in controlling the pleural effusion and prolonging the survival time. No serious complication has been experienced in our study.

Adenocarcinoma↗
PubMed1979

Cytostatic activity of peripheral blood monocytes against bronchogenic carcinoma cells in patients with lung cancer.

Cytostatic acitivity of peripheral blood monocytes against cultured cell lines of bronchogenic carcinoma was examined in patients with lung cancer. Cytostatic activity in lung cancer patients with neither augmented nor suppressed as compared with that of controls such as normal healthy persons, patients with malignancies other than lung cancer, and patients with benign respiratory diseases. There was no correlation between the cytostatic activity of monocytes and the advance of clinical stages of the disease. Conventional modalities of anticancer treatments such as surgery, radiotherapy, chemotherapy, and their combination therapy had no effect on cytostatic activity of peripheral blood monocytes. However, adequate immunotherapy with nocardia rubra cell-wall skeleton augmented the cytostatic activity of peripheral blood monocytes, although adequate immunotherapy with Mycobacterium bovis BCG cell-wall skeleton had no effect.

Adenocarcinoma↗
PubMed1979

Comparative study on antitumor effect of cell-wall skeleton of Mycobacterium bovis BCG and Nocardia rubra, with reference to T-cell dependency and independency.

Antitumor activity induced by the oil-attached cell-wall skeleton of Nocardia rubra (N-CWS) was compared with that of the oil-attached cell-wall skeleton of Mycobacterium bovis BCG (BCG-CWS) in syngeneic BALB/c tumor-host systems. In normal BALB/c mice (+/+), N-CWS exhibited stronger suppressive effect on syngeneic Br-1 and MCA tumors than did BCG-CWS. In athymic nude mice (nu/nu), BCG-CWS was as effective as N-CWS for the suppression of growth of such tumors. Suppressive effect of N-CWS treatment appears to be stronger to some extent in +/+ mice than in nu/nu mice. Immune spleen cells obtained from +/+ mice after footpad inoculation of MCA tumor cells mixed with N-CWS were effective in suppressing the MCA tumor growth, although those obtained from mice after inoculation of MCA tumor cells mixed with BCG-CWS did not exhibit a suppressive effect. This antitumor activity of immune spleen cells may be attributed to tumor-specific killer T cells. The differences of antitumor activities induced by these agents were discussed with reference to T-cell dependency and independency.

Animals↗